GILD Gilead Sciences
- 65.600
- +0.400+0.61%
Gilead Sciences News
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $117 From $120
Gilead Sciences (GILD) has an average outperform rating and a price target range of $69 to $121, according to analysts polled by Capital IQ. Price: 65.30, Change: +0.10, Percent Change: +0.15
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)--#GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Car
Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC), R1 RCM (RCM) and Gilead Sciences (GILD)
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and Sanofi (OtherSNYNF)
Gilead Sciences Is Maintained at Equal-Weight by Barclays
Gilead Sciences Is Maintained at Equal-Weight by Barclays
Barclays: Maintaining the Gilead Sciences (GILD.US) rating, adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, and the target price was adjusted from $80.00 to $76.00.
Barclays: Maintaining the Gilead Sciences (GILD.US) rating, adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, and the target price was adjusted from $80.00 to $76.00.
Gilead Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/29/2024 13.99% Barclays $80 → $76 Maintains Equal-Weight 04/26/2024 27.49% TD Cowen $90 → $85 Maintains
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Barclays Adjusts Price Target on Gilead Sciences to $76 From $80
Gilead Sciences (GILD) has an average rating of outperform and price targets ranging from $69 to $121, according to analysts polled by Capital IQ. Price: 64.38, Change: -1.04, Percent Change: -1.59
Gilead Sciences: Hold Rating With Cautious Outlook Amidst Market Challenges and Growth Uncertainties
Gilead Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Analysts Are Neutral on These Healthcare Stocks: Edwards Lifesciences (EW), Gilead Sciences (GILD)
Gilead Sciences To Go Ex-Dividend On June 14th, 2024 With 0.77 USD Dividend Per Share
April 27th - $Gilead Sciences(GILD.US)$ is trading ex-dividend on June 14th, 2024. Shareholders of record on June 14th, 2024 will receive 0.77 USD dividend per share on June 27th, 2024. The ex-div
Gilead Sciences Unusual Options Activity
Deep-pocketed investors have adopted a bullish approach towards Gilead Sciences (NASDAQ:GILD), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga un
Gilead Sciences Price Target Cut to $85.00/Share From $90.00 by TD Cowen
Gilead Sciences Price Target Cut to $85.00/Share From $90.00 by TD Cowen
Gilead Sciences Is Maintained at Sector Perform by RBC Capital
Gilead Sciences Is Maintained at Sector Perform by RBC Capital
Royal Bank of Canada: Maintaining the Gilead Sciences (GILD.US) rating, adjusted from being equal to the general market to being equal to the general market, and the target price was adjusted from $76.00 to $74.00.
Royal Bank of Canada: Maintaining the Gilead Sciences (GILD.US) rating, adjusted from being equal to the general market to being equal to the general market, and the target price was adjusted from $76.00 to $74.00.
RBC Capital Maintains Sector Perform on Gilead Sciences, Lowers Price Target to $74
RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and lowers the price target from $76 to $74.
Gilead Sciences Declares $0.77 Dividend
Analysis
Price Target
No Data
